Adma Biologics (ADMA)

$20.40 -0.41 (-1.97%)
Market Cap 4.97B
Revenue (ttm) 426.45M
Net Income (ttm) 197.67M
EPS (ttm) N/A
PE Ratio 38.57
Forward PE 32.48
Profit Margin 46.35%
Debt to Equity Ratio 0.19
Volume 2,796,668
Avg Vol 3,493,326
Day's Range N/A - N/A
Shares Out 238.73M
Stochastic %K 40%
Beta 0.47
Analysts Strong Sell
Price Target $32.33

Company Profile

ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute e...

Industry: Biotechnology
Sector: Healthcare
Phone: 201 478 5552
Fax: 201 478 5553
Address:
465 State Route 17, Ramsey, United States
StockBraker
StockBraker Jun. 16 at 7:43 PM
$ADMA We are just about 7 weeks away from 2Q25 Earnings. ADMA is expected to report on 8/6 AH. Still no updated PT from Kristen at Cantor Fitzgerald. She did; however, issue FY2026 earnings estimates on 6/9 of $1.02 per share for the year. The consensus estimate for ADMA Biologics' current full-year earnings is $0.51 per share. This 50% higher estimate is a good sign since she in the past had been a bit negative / conservative towards ADMA. EPS estimate for 2Q25 is $0.15 with FactSet estimates ranging from $0.14 - $0.18. They missed consensus EPS for 1Q25 by a penny. I think they will report inline/slightly above this time. Catalysts over the coming weeks would be an update on their share buybacks, any new positive FDA news, or Kristen issuing a $35 PT.
2 · Reply
ZacksResearch
ZacksResearch Jun. 16 at 6:22 PM
$ADMA surging on Asceniv demand — is a label expansion the next growth lever? The company is riding strong sales momentum and now aiming to expand Asceniv’s use to pediatric patients in the immunodeficiency space. See what this could mean for future revenue growth 👉 https://www.zacks.com/stock/news/2504178/adma-looks-to-expand-ascenivs-label-will-this-boost-sales?cid=sm-stocktwits-2-2504178-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2504178_TEASER
0 · Reply
hakoah
hakoah Jun. 16 at 3:35 PM
$ADMA f—k!
0 · Reply
StockBraker
StockBraker Jun. 16 at 12:51 PM
$ADMA I don't completely agree with Emanuel and Seeking Alpha tends towards the Bearish view generally. Sharing for what it's worth. https://seekingalpha.com/article/4794919-adma-biologics-slowing-growth-warrants-a-shift-to-neutral
2 · Reply
StockBraker
StockBraker Jun. 16 at 12:48 PM
$ADMA https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/the-83-return-this-week-takes-adma-biologics-nasdaqadma-shar
1 · Reply
MCMI
MCMI Jun. 15 at 4:48 PM
$ADMA Happy Father’s Day to all the fathers on here.
0 · Reply
uhhhhhhhhhhh
uhhhhhhhhhhh Jun. 15 at 4:09 PM
$ADMA just holding and letting ADMA do its thing
1 · Reply
Greatguns
Greatguns Jun. 14 at 3:40 PM
$ADMA
0 · Reply
MCMI
MCMI Jun. 14 at 1:18 AM
$ADMA Where is everybody. lol. It’s like a ghost Town here.
0 · Reply
MCMI
MCMI Jun. 14 at 1:08 AM
$ADMA why is this up 65 cents in ah. Is it very low volume.
0 · Reply
Latest News on ADMA
ADMA Biologics: Slowing Growth Warrants A Shift To Neutral (Rating Downgrade)

Jun 15, 2025, 4:11 AM EDT - 1 day ago

ADMA Biologics: Slowing Growth Warrants A Shift To Neutral (Rating Downgrade)

ADMA Biologics: Ready For More Growth Despite Q1 Earnings Miss

May 9, 2025, 3:54 AM EDT - 5 weeks ago

ADMA Biologics: Ready For More Growth Despite Q1 Earnings Miss

ADMA Biologics, Inc. (ADMA) Q1 2025 Earnings Call Transcript

May 7, 2025, 11:05 PM EDT - 5 weeks ago

ADMA Biologics, Inc. (ADMA) Q1 2025 Earnings Call Transcript

ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 4:05 PM EDT - 5 weeks ago

ADMA Biologics Announces First Quarter 2025 Financial Results and Provides Business Update

ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025

Apr 30, 2025, 7:00 AM EDT - 6 weeks ago

ADMA Biologics to Report First Quarter 2025 Financial Results on May 7, 2025

ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process

Apr 28, 2025, 7:00 AM EDT - 7 weeks ago

ADMA Biologics Announces U.S. FDA Approval of Innovative Production Yield Enhancement Process

ADMA Biologics Statement on Tariffs

Apr 7, 2025, 7:00 AM EDT - 2 months ago

ADMA Biologics Statement on Tariffs

ADMA Biologics: Premium Valuation Justified By Strong Fundamentals And Future Potential

Mar 21, 2025, 3:04 PM EDT - 3 months ago

ADMA Biologics: Premium Valuation Justified By Strong Fundamentals And Future Potential

BREAKING: Block & Leviton Investigating ADMA Biologics, Inc. for Securities Fraud Violations Following Delayed 10-K and KPMG Evaluation of Controls

Mar 4, 2025, 1:50 PM EST - 3 months ago

BREAKING: Block & Leviton Investigating ADMA Biologics, Inc. for Securities Fraud Violations Following Delayed 10-K and KPMG Evaluation of Controls

ADMA Biologics, Inc. (ADMA) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 6:24 PM EST - 3 months ago

ADMA Biologics, Inc. (ADMA) Q4 2024 Earnings Call Transcript

ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 3, 2025, 4:05 PM EST - 3 months ago

ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

ADMA Biologics to Participate in the Raymond James Institutional Investor Conference

Feb 28, 2025, 7:00 AM EST - 3 months ago

ADMA Biologics to Participate in the Raymond James Institutional Investor Conference

ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Feb 25, 2025, 7:00 AM EST - 3 months ago

ADMA Biologics to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

ADMA Biologics: Recent Pullback Is A Perfect Opportunity To Add

Feb 6, 2025, 1:46 PM EST - 4 months ago

ADMA Biologics: Recent Pullback Is A Perfect Opportunity To Add

ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility

Dec 20, 2024, 7:00 AM EST - 6 months ago

ADMA Biologics Announces Partial Paydown of Senior Term Loan Credit Facility

ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

Dec 13, 2024, 5:15 PM EST - 6 months ago

ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Urged To Contact The Schall Law Firm

ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

Dec 11, 2024, 6:15 PM EST - 6 months ago

ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm

ADMA Biologics, Inc. Is Being Investigated For Defrauding The Public And Affected Investors Are Invited To Contact The Schall Law Firm

Dec 9, 2024, 5:45 PM EST - 6 months ago

ADMA Biologics, Inc. Is Being Investigated For Defrauding The Public And Affected Investors Are Invited To Contact The Schall Law Firm

ADMA Biologics, Inc. Is Being Investigated For Fraud And Investors With Losses Are Invited To Reach Out To The Schall Law Firm

Dec 7, 2024, 5:30 PM EST - 6 months ago

ADMA Biologics, Inc. Is Being Investigated For Fraud And Investors With Losses Are Invited To Reach Out To The Schall Law Firm

ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Invited To Contact The Schall Law Firm

Dec 5, 2024, 2:15 PM EST - 6 months ago

ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Invited To Contact The Schall Law Firm

ADMA Biologics, Inc. Is Being Looked Into For Securities Fraud And Investors With Losses Are Invited To Assist The Schall Law Firm

Dec 3, 2024, 3:15 PM EST - 6 months ago

ADMA Biologics, Inc. Is Being Looked Into For Securities Fraud And Investors With Losses Are Invited To Assist The Schall Law Firm

ADMA Biologics: Capitalizing On A $20 Billion IG Market With ASCENIV

Dec 2, 2024, 8:30 AM EST - 7 months ago

ADMA Biologics: Capitalizing On A $20 Billion IG Market With ASCENIV

ADMA Biologics, Inc. Is Being Investigated For Fraud And Impacted Investors Are Invited To Contact The Schall Law Firm

Dec 1, 2024, 3:15 PM EST - 7 months ago

ADMA Biologics, Inc. Is Being Investigated For Fraud And Impacted Investors Are Invited To Contact The Schall Law Firm

ADMA Biologics, Inc. Is Being Investigated For Committing Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

Nov 29, 2024, 12:30 PM EST - 7 months ago

ADMA Biologics, Inc. Is Being Investigated For Committing Securities Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

ADMA Biologics, Inc. Is Being Investigated For Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

Nov 26, 2024, 11:00 AM EST - 7 months ago

ADMA Biologics, Inc. Is Being Investigated For Fraud And Affected Investors Are Encouraged To Contact The Schall Law Firm

The Schall Law Firm Wants Shareholders With Losses To Join An Inquiry Into ADMA Biologics Inc For Securities Related Infractions

Nov 25, 2024, 1:00 PM EST - 7 months ago

The Schall Law Firm Wants Shareholders With Losses To Join An Inquiry Into ADMA Biologics Inc For Securities Related Infractions

ADMA Biologics, Inc. Is Being Investigated For Engaging In Securities Fraud And Impacted Investors Are Urged To Contact The Schall Law Firm

Nov 24, 2024, 2:00 PM EST - 7 months ago

ADMA Biologics, Inc. Is Being Investigated For Engaging In Securities Fraud And Impacted Investors Are Urged To Contact The Schall Law Firm

ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Invited To Help The Schall Law Firm

Nov 20, 2024, 12:00 PM EST - 7 months ago

ADMA Biologics, Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Invited To Help The Schall Law Firm

ADMA Biologics, Inc. Is Being Investigated For Defrauding The Public And Affected Investors Are Urged To Contact The Schall Law Firm

Nov 18, 2024, 12:45 PM EST - 7 months ago

ADMA Biologics, Inc. Is Being Investigated For Defrauding The Public And Affected Investors Are Urged To Contact The Schall Law Firm

ADMA Biologics, Inc. Is Being Investigated For Fraud And Impacted Investors Are Encouraged To Reach Out To The Schall Law Firm

Nov 16, 2024, 11:45 AM EST - 7 months ago

ADMA Biologics, Inc. Is Being Investigated For Fraud And Impacted Investors Are Encouraged To Reach Out To The Schall Law Firm

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into ADMA Biologics Inc For Violating Securities Laws

Nov 15, 2024, 1:15 PM EST - 7 months ago

The Schall Law Firm Invites Shareholders With Losses To Join An Inquiry Into ADMA Biologics Inc For Violating Securities Laws

ADMA Biologics, Inc. Is Being Investigated For Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

Nov 14, 2024, 11:45 AM EST - 7 months ago

ADMA Biologics, Inc. Is Being Investigated For Fraud And Affected Investors Are Urged To Contact The Schall Law Firm

ADMA Biologics, Inc. Is Being Investigated For Defrauding Investors And Those With Losses Are Urged To Reach Out To The Schall Law Firm

Nov 10, 2024, 11:00 AM EST - 7 months ago

ADMA Biologics, Inc. Is Being Investigated For Defrauding Investors And Those With Losses Are Urged To Reach Out To The Schall Law Firm

StockBraker
StockBraker Jun. 16 at 7:43 PM
$ADMA We are just about 7 weeks away from 2Q25 Earnings. ADMA is expected to report on 8/6 AH. Still no updated PT from Kristen at Cantor Fitzgerald. She did; however, issue FY2026 earnings estimates on 6/9 of $1.02 per share for the year. The consensus estimate for ADMA Biologics' current full-year earnings is $0.51 per share. This 50% higher estimate is a good sign since she in the past had been a bit negative / conservative towards ADMA. EPS estimate for 2Q25 is $0.15 with FactSet estimates ranging from $0.14 - $0.18. They missed consensus EPS for 1Q25 by a penny. I think they will report inline/slightly above this time. Catalysts over the coming weeks would be an update on their share buybacks, any new positive FDA news, or Kristen issuing a $35 PT.
2 · Reply
ZacksResearch
ZacksResearch Jun. 16 at 6:22 PM
$ADMA surging on Asceniv demand — is a label expansion the next growth lever? The company is riding strong sales momentum and now aiming to expand Asceniv’s use to pediatric patients in the immunodeficiency space. See what this could mean for future revenue growth 👉 https://www.zacks.com/stock/news/2504178/adma-looks-to-expand-ascenivs-label-will-this-boost-sales?cid=sm-stocktwits-2-2504178-teaser&ADID=SYND_STOCKTWITS_TWEET_2_2504178_TEASER
0 · Reply
hakoah
hakoah Jun. 16 at 3:35 PM
$ADMA f—k!
0 · Reply
StockBraker
StockBraker Jun. 16 at 12:51 PM
$ADMA I don't completely agree with Emanuel and Seeking Alpha tends towards the Bearish view generally. Sharing for what it's worth. https://seekingalpha.com/article/4794919-adma-biologics-slowing-growth-warrants-a-shift-to-neutral
2 · Reply
StockBraker
StockBraker Jun. 16 at 12:48 PM
$ADMA https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-adma/adma-biologics/news/the-83-return-this-week-takes-adma-biologics-nasdaqadma-shar
1 · Reply
MCMI
MCMI Jun. 15 at 4:48 PM
$ADMA Happy Father’s Day to all the fathers on here.
0 · Reply
uhhhhhhhhhhh
uhhhhhhhhhhh Jun. 15 at 4:09 PM
$ADMA just holding and letting ADMA do its thing
1 · Reply
Greatguns
Greatguns Jun. 14 at 3:40 PM
$ADMA
0 · Reply
MCMI
MCMI Jun. 14 at 1:18 AM
$ADMA Where is everybody. lol. It’s like a ghost Town here.
0 · Reply
MCMI
MCMI Jun. 14 at 1:08 AM
$ADMA why is this up 65 cents in ah. Is it very low volume.
0 · Reply
AgentMulder
AgentMulder Jun. 13 at 6:29 PM
$ADMA 5B MC going to go higher in due time driven by Rev ⬆️ and margins ⬆️ due to improved mfg process. Happy to wait for $25-35 as Rev estimates swing from 1B to 2B👍
0 · Reply
GoldmanSlaps
GoldmanSlaps Jun. 13 at 3:34 PM
$ADMA this move makes 0 sense
1 · Reply
MCMI
MCMI Jun. 13 at 3:30 PM
$ADMA will she go green today?
0 · Reply
ItsRCB
ItsRCB Jun. 12 at 7:52 PM
$ADMA how many shares are people expecting to have been repurchased for the quarter? Something like 1 million shares / $20-25 million spent? Hoping management tried to scoop up a good amount when the price was sitting under 20, but don't expect a huge spend yet.
1 · Reply
Santi_19
Santi_19 Jun. 12 at 5:19 PM
$ADMA ADMA Biologics Reaches Crucial Milestone with FDA Approval and Strategic Investments Caracas, Venezuela In April 2025, ADMA Biologics secured FDA approval for its innovative yield enhancement process, boosting production by around 20% using the same volume of plasma. This breakthrough is set to drive sustained revenue and profit growth, establishing the company as a leader in immunoglobulin therapies and biologics On June 9 2025 Director Jerrold B Grossman sold 10000 shares, valued at approximately $213100 amid impressive performance, including Q1 2025 revenues of $114.8 million a 40% yoy increase. Major institutional investors, such as First Citizens Bank & Trust Co. Veracity Capital LLC and Summit Global Investments, have substantially increased their stakes, reinforcing market confidence in ADMAs strategic direction. These developments mark both immediate success and a strategic shift toward scalable, sustainable growth, potentially heralding a new era in the biotech sector.
0 · Reply
StockBraker
StockBraker Jun. 11 at 10:09 PM
$ADMA That's nice Kristen, but how about an updated PT?? ⌚👀
1 · Reply
Johnny_Lever
Johnny_Lever Jun. 11 at 7:06 PM
$ADMA Been here a few times lately.
2 · Reply
BBop
BBop Jun. 11 at 5:19 PM
$ADMA
0 · Reply
ivanhoff
ivanhoff Jun. 11 at 4:30 PM
$ADMA sold off after their last earnings but it held above its 200dma and it continues to work on a new base.
0 · Reply
StockBraker
StockBraker Jun. 11 at 4:29 PM
$ADMA Sure feels nice.
0 · Reply
jconnors7
jconnors7 Jun. 11 at 3:02 PM
$ADMA large seller completed order...back to higher earnings and guidance come august. $30+ this year. $40+ 2027. BO in 2026 or 2027 at $50+. PRINT THAT!!!
1 · Reply
ncost1
ncost1 Jun. 11 at 2:57 PM
$ADMA let’s go Adam!!!!
0 · Reply